Bobby Sandage is currently President and CEO of Euclises, Chairman of the Board of Immunophotonics, member of the board of directors of EDIS, and a member of the Cultivation Capital life sciences fund investment committee. He was formerly President and CEO of Coronado Biosciences and VP of Embedded Therapeutics at Covidien Pharmaceuticals. He was also previously executive vice president, research and development, and chief scientific officer at Indevus Pharmaceuticals. Bobby has previously held senior drug development positions within the cardiovascular research and development division of DuPont Merck Pharmaceutical Company and with the medical department of DuPont Critical Care. Bobby is an adjunct professor in the department of pharmaceutical sciences at the Southern Illinois University at Edwardsville School of Pharmacy. Bobby received his Ph.D. in clinical pharmacy from Purdue University and his B.S. in pharmacy from the University of Arkansas.